Biography
Ellen T. Matloff founded the Yale Cancer Genetic Counseling program, served as its director and a faculty member at Yale School of Medicine for 18 years, and was a lead plaintiff in the SCOTUS BRCA gene patent case of 2013. She works closely with patient advocates in the areas of genetic counseling and testing, and direct-to-consumer (DTC) genetic testing, and is an expert in responsible return of genetic test results and scalable updating for population studies, health care systems, and precision medicine partners. Matloff serves as the Forbes.com contributor on genetic counseling, genetic testing, and digital health.

Biography
In her current role, Suzanne focuses on commercial strategy and growth for Tempus developing and executing partnerships with organizations to improve healthcare value and outcomes by leveraging molecular and clinical data. Value creation for commercial payers, benefit managers and group purchasing organizations is where she focuses. Dr. Belinson is especially interested in applications of data to power solutions for the transition to and management of value based care. Prior to Tempus, Dr. Belinson served as Executive Director, Clinical Markets, at the Blue Cross Blue Shield Association where she led the sales and market development as well as day to day operations of Evidence Street. Dr. Belinson received her bachelor’s degree from Cleveland State University, a Masters in Public Health from the University of Pittsburgh, and a PhD in Epidemiology from the University of North Carolina at Chapel Hill.

Biography
Ms. Perettie is passionate about improving the care of cancer patients and brings more than two decades of scientific and commercial experience with global biopharmaceutical organizations. Prior to joining Foundation Medicine, Ms. Perettie served as Senior Vice President in global oncology product strategy for Roche’s Oncology unit. Ms. Perettie began her tenure at Genentech as a program team leader for bevacizumab, and she led several successful therapy launches in the U.S. and abroad for Roche and Genentech across the oncology portfolio, including in lung cancer, breast cancer and hematology. In 2012, Ms. Perettie took a hiatus from Genentech to join Sarah Cannon Research Institute as President, Global Development Innovations where she gained invaluable insights into the day-to-day care of people living with cancer. Before joining Genentech, Ms. Perettie lead portfolio management at IVAX Pharmaceuticals and was the director of global program management at Élan Corporation. Her pharmaceutical experience began as a research scientist associate director role at Chiron Corporation.

Biography
Ms. Nagy is a licensed genetic counselor and Director of Medical Affairs at Guardant Health, Inc. Prior to joining Guardant, she was an Associate Professor in the Department of Clinical Internal Medicine at the Ohio State University James Cancer Hospital. She has over 15 years of experience in counseling patients with hereditary cancer syndromes and extensive experience in translational research, serving as a co-PI on an NCI-funded program project and SPORE. She is a past president of the National Society of Genetic Counselors and continues her leadership role in the NSGC as co-director of the NSGC Leadership Development Program.

Biography
Dr. Shari Brown joined NeoGenomics as a Molecular Pathologist in 2018. Dr. Brown previously served as Director of Molecular Pathology and Informatics and Interim Director of Histology and Gross Pathology in addition to her role as Surgical Pathologist for Memphis Pathology Group. Dr. Brown was a Clinical Instructor/Advanced Surgical Pathology Fellow at East Carolina University, Brody School of Medicine and completed her fellowship in Molecular & Genetic Pathology at Oregon Health & Science University, and her residency at University of Hawaii. Dr. Brown’s publications include a chapter on the molecular pathology of solid tumors in Cheng and Bostwick’s Essentials of Anatomic Pathology. Dr. Brown’s areas of interest and investigation include structured educational training modules for pathology education and training, error correction techniques for next-generation sequencing data, use of clinical bioinformatics tools for managing cancer patients, and somatic mutations related to disease progression in acute myeloid leukemia.